Cargando…

Non-small-cell lung cancer: how to manage EGFR-mutated disease

The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped the therapeutic algorithm both in the first-line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pecci, Federica, Cantini, Luca, Metro, Giulio, Ricciuti, Biagio, Lamberti, Giuseppe, Farooqi, Ammad Ahmad, Berardi, Rossana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354708/ https://www.ncbi.nlm.nih.gov/pubmed/35975029 http://dx.doi.org/10.7573/dic.2022-4-1

Ejemplares similares

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage RET-positive disease
por: Andrini, Elisa, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
por: Marinelli, Daniele, et al.
Publicado: (2022)

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
por: De Giglio, Andrea, et al.
Publicado: (2023)

Advanced non-small-cell lung cancer: how to manage non-oncogene disease
por: De Giglio, Andrea, et al.
Publicado: (2022)

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives
por: Cognigni, Valeria, et al.
Publicado: (2022)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
por: Ricciuti, Biagio, et al.
Publicado: (2017)

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
por: Ricciuti, Biagio, et al.
Publicado: (2015)

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS(G12C)-Mutant Non–Small-Cell Lung Cancer
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Non-coding RNAs in lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2014)

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
por: Koulouris, Andreas, et al.
Publicado: (2022)

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
por: Pecci, Federica, et al.
Publicado: (2021)

Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
por: Cantini, Luca, et al.
Publicado: (2021)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
por: De Giglio, Andrea, et al.
Publicado: (2022)

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
por: Metro, Giulio, et al.
Publicado: (2015)

Regulation of Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer
por: Farooqi, Ammad Ahmad, et al.
Publicado: (2021)

How to Treat EGFR-Mutated Non–Small Cell Lung Cancer
por: Belani, Neel, et al.
Publicado: (2023)

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
por: Paglialunga, Luca, et al.
Publicado: (2016)

Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic
por: Ballatore, Zelmira, et al.
Publicado: (2020)

Regulation of ROCK1/2 by long non-coding RNAs and circular RNAs in different cancer types
por: Farooqi, Ammad Ahmad, et al.
Publicado: (2022)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
por: Galvez‐Nino, Marco, et al.
Publicado: (2022)

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
por: Berardi, Rossana, et al.
Publicado: (2013)

Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study
por: Liguori, Carolina, et al.
Publicado: (2023)

Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia
por: Giampieri, Riccardo, et al.
Publicado: (2019)

Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing
por: Giampieri, Riccardo, et al.
Publicado: (2020)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
por: Cantini, Luca, et al.
Publicado: (2021)

Gut Microbiota in Lung Cancer: Where Do We Stand?
por: Georgiou, Konstantinos, et al.
Publicado: (2021)

Management of lung cancer patients during COVID-19 pandemic: dos, don’ts and don’t knows
por: Torniai, Mariangela, et al.
Publicado: (2022)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
por: Lenci, Edoardo, et al.
Publicado: (2021)

Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2022)

Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer
por: Koç Erbaşoğlu, Öncü, et al.
Publicado: (2018)

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
por: Ricciuti, Biagio, et al.
Publicado: (2018)

Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients
por: Bittoni, Alessandro, et al.
Publicado: (2021)

BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma
por: Murrone, Albero, et al.
Publicado: (2021)

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma
por: Hakozaki, Taiki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vagjkofuu5hgv6cj1eujlpv3ms